Pressure BioSciences has launched a commercial biopharmaceutical contract service business after acquiring a protein therapeutics platform that it says reduces challenges and manufacturing costs of the growing drug market.
Patheon and JLL are to end the legal actions between them by entering into a litigation settlement which establishes a board of directors and limits JLL acquiring additional restricted voting shares before April 27 2012.
Biotech company Progen has decided to manufacture its new
anti-cancer drug in-house rather than outsource it in order to save
on costs after the FDA gave the thumbs up for the manufacture of
the drug for its upcoming phase III clinical...